Carbamazepine augmentation for schizophrenia: How good is the evidence?

Journal of Clinical Psychiatry

Volumn 63, Issue 3, 2002, Pages 218-224

  Leucht, Stefan ^a   McGrath, John ^a   White, Paul ^a   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; VALPROIC ACID;

AGGRESSION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; META ANALYSIS; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0036107304     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0308     Document Type: Article

References (43)

1. Psychopharmacologic treatment of schizophrenia
2. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
3. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
4. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia
5. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review
6. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications
7. Practice guideline for the treatment of patients with schizophrenia
8. At issue, translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
9. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
10. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
11. Publication bias in clinical research
12. Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews
13. The science of reviewing research
14. Limitations of controlled augmentation trials in schizophrenia
15. Rational polypharmacy in schizophrenia
16. Carbamazepine for schizophrenia
17. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
18. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
19. The brief psychiatric rating scale
20. Detecting skewness from summary information
21. Carbamazepine maintenance treatment in outpatient schizophrenics
22. Controlled cross-over comparison of carbamazepine with perphenazine in schizophrenic psychoses
23. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities
24. Carbamazepine as an adjunct of antipsychotic therapy
25. La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias
26. Kombinationstherapie mit neuroleptika und carbamazepin: Eine kontrollierte studie
27. Efficacité comparée de la bromocriptine, de la carbamazépine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrènes chroniques résistants
28. A double-blind trial of carbamazepine in negative symptom schizophrenia
29. Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia
30. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients
31. Discrepancies between meta-analyses and subsequent large randomized, controlled trials
32. Carbamazepine induced reduction of blood levels of haloperidol in chronic schizophrenia
33. Double blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol
34. Carbamazepine and haloperidol versus placebo and haloperidol in excited psychoses
35. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders
36. Carbamazepine in violent non-epileptic schizophrenics
37. Carbamazepine in treatment of violent schizophrenics
38. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: A case report
39. Pharmacokinetics of haloperidol: An update
40. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia
41. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?